Researchers from the Washington University School of Medicine have found that GLP-1 weight loss and diabetes drugs like Ozempic, Wegovy, Mounjaro and Zepbound could potentially address a range of health conditions such as heart disease, sleep apnea, kidney and liver conditions. The study, led by Dr. Ziyad Al-Aly, found that people taking these drugs reduced their risk of developing addictions and reduced the negative consequences of addictive behaviors such as hospitalizations, overdose, and death. The research was published in the BMJ and used health records from over 600,000 people in the Department of Veterans Affairs system, who were diagnosed with diabetes and prescribed GLP/Mounjaros. The researchers also found that the weight loss drugs were beneficial in helping people who already had a substance use disorder. They found that these drugs also reduced the risk of emergency department visits by 29%, hospitalizations due to their addiction by 26%, overdose by 39%, and deaths from drug-related causes by 50%. The study could pave the way for a new class of drugs that could prevent and treat different types of addictions. However, more studies need to be conducted to better understand how the medications should be used in these cases.